Article
CYTOPLASMIC-MEMBRANE EGFR PREDICTS EXPANDED RAS MUTATION STATUS IN COLORECTAL CARCINOMAS?
Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery - 1 Jan 2021
Pinto Thiago David Alves, Alves Thaís David das Neves, Pinto Sebastião Alves, Oliveira Enio Chaves
Abstract excerpt
BACKGROUND: Inhibitors of the epidermal growth factor (EGFR) represent an effective therapeutic option for patients with metastatic colorectal carcinoma, free of activating mutations in KRAS and NRAS. However, the research of mutations is of high cost and scarcely accessible. The expression of the EGFR by immunohistochemistry predicting the mutation status of the expanded RAS (KRAS and NRAS), may allow treatment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.